# Dr. Ramesh Byrapaneni

> Dr. Ramesh Byrapaneni is a seed investor at Endiya Partners backing Health Care and Medical. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Endiya Partners](https://shizune.co/investors/profile/endiya-partners)
- Location: Hyderabad, India
- Total investments: 14
- Last investment: Mar 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/rameshbyrapaneni/
- X (Twitter): http://twitter.com/Rameshbyrapanen
- Website: https://x.com/Rameshbyrapanen

Dr. Ramesh Byrapaneni is a seed investor at Endiya Partners in Hyderabad focused on Health Care and Medical. Dr. Ramesh Byrapaneni - Co-Founder & Managing Director @ Endiya Partners

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 36% |
| Medical | 2 | 14% |
| Software | 2 | 14% |
| Biotechnology | 2 | 14% |
| Machine Learning | 2 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 36% |
| Series A | 4 | 29% |
| Series B | 2 | 14% |
| Series C | 1 | 7% |
| Funding Round | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AquaExchange | AquaExchange is a technology platform for shrimp and fish farmers. | $8M | Series B | Mar 10, 2026 |  |
| SigTuple | SigTuple's vision is to revolutionise the global medical diagnostic space through data driven intelligence. They aim to create a data driven, machine learned, cloud based solution for detection of anomalies and trends in medical data, which improves the accuracy and efficiency of disease diagnosis. | $3.9M | Series C | Aug 06, 2024 |  |
| AquaExchange | AquaExchange is a technology platform for shrimp and fish farmers. | $6M | Series A | Jan 19, 2024 |  |
| Sugar.fit | Sugar.fit is the proprietor of a diabetic treatment company that aims to help individuals overcome diabetes easily and sustainably. The company provides a research-driven treatment plan that involves technology, diabetes experts, and individualized strategies to help individuals live normal lives, allowing patients to obtain medical advice throughthe app. | $10.9M | Series A | Oct 31, 2023 |  |
| NKure Therapeutics | NKure Therapeutics develops NK therapy methods for cancer patients by utilising research and scientific techniques |  | Seed | Apr 26, 2023 |  |
| SigTuple | SigTuple's vision is to revolutionise the global medical diagnostic space through data driven intelligence. They aim to create a data driven, machine learned, cloud based solution for detection of anomalies and trends in medical data, which improves the accuracy and efficiency of disease diagnosis. | $4.2M | Series C | Mar 01, 2023 |  |
| Eyestem | Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treatincurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety. | $6.4M | Series A | Aug 08, 2022 |  |
| AquaExchange | AquaExchange is a technology platform for shrimp and fish farmers. | $3M | Seed | Jun 30, 2022 |  |
| Karkinos Healthcare | Karkinos Healthcare is technology-driven oncology focussed managed health care platform for the early detection and diagnosis of common cancers. |  | Seed | Jan 12, 2022 |  |
| Sugar.fit | Sugar.fit is the proprietor of a diabetic treatment company that aims to help individuals overcome diabetes easily and sustainably. The company provides a research-driven treatment plan that involves technology, diabetes experts, and individualized strategies to help individuals live normal lives, allowing patients to obtain medical advice throughthe app. | $10M | Seed | Sep 02, 2021 |  |

10 of 14 investments shown.

## Co-investors
- [Accion Ventures](https://shizune.co/investors/profile/venture-lab) — VC Fund, 5 deals together
- [Cult.fit](https://shizune.co/investors/profile/curefit) — VC Fund, 2 deals together
- [Natco Pharma](https://shizune.co/investors/profile/natco-pharma) — VC Fund, 2 deals together
- [Ocean 14 Capital](https://shizune.co/investors/profile/ocean-14-capital) — VC Fund, 2 deals together
- [Tanglin Venture Partners](https://shizune.co/investors/profile/tanglin-venture-partners) — VC Fund, 2 deals together
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund, 1 deal together

## About Endiya Partners

VC Fund · Hyderabad, India

Endiya Partners is an early-stage venture capital firm with a proven track record of backing high-growth product startups. Leveraging their deep domain expertise and decades of entrepreneurial and operational experience, the Endiya team plays a pivotal role in building successful, scalable businesses. The firm’s notable portfolio includes severalcategory-defining companies such as Darwinbox, Kissht, SigTuple, Zluri, Qapita, Eyestem, Scrut Automation, Sugar.fit, and AquaExchange.In addition to financial support, Endiya also provides strategic and operational assistance to its portfolio companies, such as idea and market validation, management team development, business model optimization, customer and partner acquisition, and much more. Collectively, Endiya's Investments team has a comprehensive understanding of the industries, with domain expertise ranging from SaaS to Information Security to Semiconductors to Healthcare & Life Sciences to Financial Services.Founded in 2015, Endiya Partners has $100M under management. For more information, visit: https://endiya.com/

5 contacts available at Endiya Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Anvesh Ramineni | Venture Partner | https://shizune.co/investors/profile/anvesh-ramineni |
| Dr. Ramesh Byrapaneni | Co-Founder & Managing Director | https://shizune.co/investors/profile/dr-ramesh-byrapaneni |
| Abhiram Katta | Director | https://shizune.co/investors/profile/abhiram-katta |
| Bavatarak Pamidi | Senior Analyst | https://shizune.co/investors/profile/bavatarak-pamidi |
| Medha Kannapally | Associate | https://shizune.co/investors/profile/medha-kannapally-4deb |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Dr. Ramesh Byrapaneni invest in?

Dr. Ramesh Byrapaneni invests primarily in Health Care, Medical and Software startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dr. Ramesh Byrapaneni last invest?

The most recent investment recorded for Dr. Ramesh Byrapaneni closed in Mar 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co